FR15C0094I1 - - Google Patents

Info

Publication number
FR15C0094I1
FR15C0094I1 FR15C0094C FR15C0094I1 FR 15C0094 I1 FR15C0094 I1 FR 15C0094I1 FR 15C0094 C FR15C0094 C FR 15C0094C FR 15C0094 I1 FR15C0094 I1 FR 15C0094I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23001755&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR15C0094(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR15C0094I1 publication Critical patent/FR15C0094I1/fr
Application granted granted Critical
Publication of FR15C0094I2 publication Critical patent/FR15C0094I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
FR15C0094C 2001-01-23 2015-12-21 Vaccin de meningocoque tri- ou tetravalent prepare avec un conjugue de polysaccharide et de crm197 Active FR15C0094I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26343501P 2001-01-23 2001-01-23
EP02707551A EP1355673B1 (fr) 2001-01-23 2002-01-22 Vaccin meningococcique polyvalent prrepare avec un conjugue de polysaccharide et de proteine

Publications (2)

Publication Number Publication Date
FR15C0094I1 true FR15C0094I1 (fr) 2016-01-22
FR15C0094I2 FR15C0094I2 (fr) 2017-05-19

Family

ID=23001755

Family Applications (3)

Application Number Title Priority Date Filing Date
FR12C0072C Active FR12C0072I2 (fr) 2001-01-23 2012-11-29 Vaccin meningococcique polyvalent prrepare avec un conjugue de polysaccharide et de proteine
FR15C0094C Active FR15C0094I2 (fr) 2001-01-23 2015-12-21 Vaccin de meningocoque tri- ou tetravalent prepare avec un conjugue de polysaccharide et de crm197
FR22C1001C Active FR22C1001I1 (fr) 2001-01-23 2022-01-06 Vaccin conjugué de protéine et de polysaccharide pour méningococcie polyvalente

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR12C0072C Active FR12C0072I2 (fr) 2001-01-23 2012-11-29 Vaccin meningococcique polyvalent prrepare avec un conjugue de polysaccharide et de proteine

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR22C1001C Active FR22C1001I1 (fr) 2001-01-23 2022-01-06 Vaccin conjugué de protéine et de polysaccharide pour méningococcie polyvalente

Country Status (38)

Country Link
US (9) US8722062B2 (fr)
EP (3) EP1355673B1 (fr)
JP (6) JP2005504718A (fr)
KR (2) KR100947751B1 (fr)
CN (1) CN100556459C (fr)
AP (1) AP1897A (fr)
AU (2) AU2007216743A1 (fr)
BE (3) BE2012C050I2 (fr)
BR (1) BRPI0206672B8 (fr)
CA (1) CA2435681C (fr)
CR (1) CR7035A (fr)
CY (2) CY1113072T1 (fr)
DK (2) DK2332581T3 (fr)
EA (1) EA006947B1 (fr)
EC (1) ECSP034701A (fr)
ES (3) ES2892316T3 (fr)
FR (3) FR12C0072I2 (fr)
GE (1) GEP20053691B (fr)
HR (1) HRP20030598B1 (fr)
HU (2) HU230490B1 (fr)
IL (3) IL157060A0 (fr)
IS (1) IS6881A (fr)
LT (1) LT5177B (fr)
LU (1) LU92108I2 (fr)
LV (1) LV13128B (fr)
MX (2) MXPA03006561A (fr)
NO (1) NO20033816L (fr)
NZ (2) NZ602682A (fr)
OA (1) OA12590A (fr)
PL (1) PL226184B1 (fr)
PT (2) PT2332581E (fr)
RO (1) RO122761B1 (fr)
SI (1) SI21352A (fr)
TN (1) TNSN03041A1 (fr)
UA (1) UA92579C2 (fr)
WO (1) WO2002058737A2 (fr)
YU (1) YU66103A (fr)
ZA (1) ZA200306176B (fr)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
DK2332581T3 (en) 2001-01-23 2015-10-05 Sanofi Pasteur Inc Tri- or tetravalent meningococcal polysaccharide-crm197 conjugate vaccine
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
AU2014218428B2 (en) * 2001-06-20 2016-08-25 Glaxosmithkline Biologicals Sa Capsular polysaccharide solubilisation and combination vaccines
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
DE60328481D1 (de) * 2002-05-14 2009-09-03 Novartis Vaccines & Diagnostic Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
AU2003299501A1 (en) * 2002-05-16 2004-05-04 Aventis Pasteur, Inc. Animal component free meningococcal polysaccharide fermentation and seedbank development
US20040096461A1 (en) * 2002-07-30 2004-05-20 Baxter Healthcare Corporation Chimeric multivalent polysaccharide conjugate vaccines
BR0316271A (pt) * 2002-11-14 2005-10-11 Inst Finlay Ct De Investigacio Método para a obtenção de preparados vacinais conjugados multivalentes, composição vacinal multivalente e uso da mesma
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CN101926988B (zh) 2003-01-30 2014-06-04 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
US9296795B2 (en) * 2003-03-07 2016-03-29 Wyeth Holdings, Llc. Polysaccharide-staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
WO2005004909A2 (fr) * 2003-05-07 2005-01-20 Aventis Pasteur, Inc. Methode permettant d'obtenir une immunogenicite amelioree par rapport a la vaccination meningococcique
CA2528007C (fr) * 2003-06-02 2012-03-27 Chiron Corporation Compositions immunogenes basees sur des microparticules comprenant des antigenes contenant de l'anatoxine adsorbee et des polysaccharides
US20070020293A1 (en) * 2003-06-23 2007-01-25 Michon Francis J Vaccines against group neisseria meningitidis and meningococcal combinations thereof
CA2530434A1 (fr) * 2003-06-23 2005-01-06 Aventis Pasteur, Inc. Procede d'immunisation contre la bacterie neisseria meningitidis serogroupes a et c
CA2885040C (fr) 2003-10-02 2018-10-30 Novartis Vaccines And Diagnostics S.R.L. Vaccins liquides contre de multiples serogroupes meningococciques
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0408978D0 (en) 2004-04-22 2004-05-26 Chiron Srl Meningococcal fermentation for preparing conjugate vaccines
AU2011204789B2 (en) * 2004-04-22 2013-07-11 Glaxosmithkline Biologicals S.A. Immunising against meningococcal serogroup Y using proteins
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
PL1740217T3 (pl) * 2004-04-30 2012-03-30 Novartis Ag Szczepienie koniugatem meningokokowym
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
AU2005279821A1 (en) * 2004-08-30 2006-03-09 Sanofi Pasteur, Inc. Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
GB0419846D0 (en) 2004-09-07 2004-10-13 Chiron Srl Vaccine adjuvants for saccharides
JP2008513541A (ja) * 2004-09-21 2008-05-01 サノフィ パストゥール インコーポレイテッド 多価髄膜炎菌誘導体化多糖−タンパク質複合体およびワクチン
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
EP1871411A4 (fr) 2005-04-18 2010-07-21 Novartis Vaccines & Diagnostic Procede pour exprimer un antigene de surface de virus de l'hepatite b afin de preparer un vaccin
PE20110072A1 (es) 2005-06-27 2011-02-04 Glaxosmithkline Biolog Sa Composicion inmunogenica
US8007807B2 (en) 2005-09-01 2011-08-30 Novartis Vaccines And Diagnostics Gmbh Multiple vaccination including serogroup C meningococcus
US20070065462A1 (en) * 2005-09-21 2007-03-22 Ryall Robert P Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
BRPI0708849B1 (pt) * 2006-03-17 2022-05-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Métodos para a preparação de conjugados imunogênicos multivalentes complexos, os referidos conjugados, e composições farmacêuticas
EP2004225B1 (fr) 2006-03-22 2012-04-25 Novartis AG Schema posologique pour une immunisation avec des conjugues de meningocoques
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
WO2007116409A2 (fr) 2006-04-11 2007-10-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Vaccins améliorés comprenant des supports peptidiques multimères dérivés de la hsp60
BRPI0811979A2 (pt) 2007-06-04 2014-10-21 Novartis Ag Formulação para vacinas de meningite
PL2200642T3 (pl) 2007-10-19 2012-09-28 Novartis Ag Preparaty szczepionek meningokokowych
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
CA2747340A1 (fr) 2008-12-17 2010-06-24 Novartis Ag Vaccins meningococciques comprenant un recepteur de l'hemoglobine
US8003112B2 (en) * 2009-04-16 2011-08-23 Howard University Meningococcal and pneumococcal conjugate vaccine and method of using same
JP5781542B2 (ja) 2009-12-30 2015-09-24 ノバルティス アーゲー Ｅ．ｃｏｌｉキャリアタンパク質に結合体化した多糖免疫原
CN102802662A (zh) 2010-03-18 2012-11-28 诺华有限公司 用于脑膜炎球菌血清组b的含佐剂疫苗
WO2012025873A2 (fr) 2010-08-23 2012-03-01 Wyeth Llc Formulations stables des antigènes rlp2086 de neisseria meningitidis
ES2744471T3 (es) * 2010-09-04 2020-02-25 Glaxosmithkline Biologicals Sa Ensayos de anticuerpos bactericidas para evaluar la inmunogenia y la potencia de vacunas de sacárido capsular meningocócico
JP5976652B2 (ja) 2010-09-10 2016-08-24 ワイス・エルエルシー 髄膜炎菌ｏｒｆ２０８６抗原の非脂質化変異体
CA2860331A1 (fr) 2010-12-24 2012-06-28 Novartis Ag Composes
CN103533954B (zh) 2011-03-02 2015-09-09 诺华股份有限公司 含较低剂量的抗原和/或佐剂的联合疫苗
WO2013009564A1 (fr) 2011-07-08 2013-01-17 Novartis Ag Procédé de ligature de la tyrosine
CA2854934A1 (fr) 2011-11-07 2013-05-16 Novartis Ag Molecule porteuse comprenant un antigene spr0096 et un antigene spr2021
WO2013132043A1 (fr) 2012-03-08 2013-09-12 Novartis Ag Vaccins combinés comprenant des agonistes du tlr4
EP2823312B1 (fr) 2012-03-08 2019-08-07 GlaxoSmithKline Biologicals SA In vitro essai d'activite des vaccins a base de proteines méningococciques
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
EP3485906A1 (fr) 2012-03-09 2019-05-22 Pfizer Inc Compositions de neisseria meningitidis et procédés associés
CN102660602B (zh) * 2012-04-17 2015-03-25 江苏康泰生物医学技术有限公司 快速纯化细菌荚膜多糖的方法
MX2014014067A (es) 2012-05-22 2015-02-04 Novartis Ag Conjugado de serogrupo x de meningococo.
PT3421051T (pt) * 2012-08-16 2020-06-26 Pfizer Processos e composições de glicoconjugação
EP2892553A1 (fr) 2012-09-06 2015-07-15 Novartis AG Vaccins combinatoires avec méningococcus de sérogroupe b et d/t/p
CN102861326A (zh) * 2012-09-19 2013-01-09 天津康希诺生物技术有限公司 流脑多糖-蛋白质缀合疫苗及制备方法
CA2894260A1 (fr) 2012-12-18 2014-06-26 Glaxosmithkline Biologicals S.A. Conjugues de protection contre la diphterie et/ou le tetanos
CA2903716C (fr) 2013-03-08 2019-04-09 Pfizer Inc. Polypeptides immunogenes de fusion
EP2976101B1 (fr) * 2013-03-18 2020-08-19 GlaxoSmithKline Biologicals S.A. Procédé de traitement
MX2016000393A (es) 2013-07-11 2016-10-26 Novartis Ag Modificaciones de proteinas quimioenzimaticas de lisina utilizando transglutaminasa microbiana.
KR20180099912A (ko) 2013-09-08 2018-09-05 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
EP3148577B1 (fr) 2014-05-24 2021-01-20 Biological E Limited Nouveau vaccin conjugué méningococcique semi-synthétique
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3258850B1 (fr) 2015-02-20 2020-06-24 Bayer HealthCare LLC Agent d'imagerie de contraste à fluide à dégagement de gaz dissous
KR20160011136A (ko) 2015-03-25 2016-01-29 한국기계연구원 내식성이 향상된 마그네슘 합금 및 이를 이용하여 제조한 마그네슘 합금 부재의 제조방법
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
PL3397324T3 (pl) 2015-12-30 2022-10-24 Ascendis Pharma A/S Automatyczny wstrzykiwacz z układem utrzymywania wkładu
KR102204927B1 (ko) 2016-07-25 2021-01-19 에스케이바이오사이언스(주) 피막 다당류-단백질 접합 백신의 품질 평가 방법
US20180064801A1 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
AU2017321863A1 (en) 2016-09-02 2019-04-11 Sanofi Pasteur, Inc. Neisseria meningitidis vaccine
SG10202111092UA (en) 2017-01-31 2021-11-29 Pfizer Neisseria meningitidis compositions and methods thereof
WO2019198096A1 (fr) * 2018-04-11 2019-10-17 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Composition de vaccin méningococcique tétravalente et son procédé de préparation
EP3632465A1 (fr) 2018-10-03 2020-04-08 Sanofi Pasteur Inc. Immunisation combinée contre la méningite à méningocoques et le papillomavirus humain
US20220125908A1 (en) * 2019-02-14 2022-04-28 University Of Florida Research Foundation, Incorporated Honeybee commensal snodgrassella alvi vaccine against pathogenic neisseriaceae
CN110903388B (zh) * 2019-12-03 2024-01-02 兰州生物制品研究所有限责任公司 一种将脑膜炎球菌抗血清去交叉反应的方法
BR112022011714A2 (pt) 2019-12-17 2022-09-06 9286 3620 Quebec Inc Sistemas de distribuição oral com base em formação in situ de coacervados de proteína/polissacarídeo
KR102610292B1 (ko) 2021-02-10 2023-12-04 에스케이바이오사이언스(주) 스트랩토코커스 뉴모니애 다당류와 운반체 단백질의 접합체 제조 방법
US20220265805A1 (en) 2021-02-19 2022-08-25 Sanofi Pasteur Inc. Meningococcal b recombinant vaccine
WO2023200704A1 (fr) 2022-04-11 2023-10-19 Sanofi Pasteur Inc. Conjugaison protéine-saccharide avec du cyanoborohydrure de sodium
WO2024030931A1 (fr) 2022-08-03 2024-02-08 Sanofi Pasteur Inc. Composition immunogène à adjuvant contre neisseria meningitidis b

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351761A (en) 1978-05-15 1982-09-28 Research Corporation Purified antigen to test for Neisseria gonorrhoeae antibodies
US4404371A (en) 1981-01-14 1983-09-13 Battelle Memorial Institute Carboxymethylcellulose with carbonate bridges and preparation thereof
US4351762A (en) * 1981-03-10 1982-09-28 Bioresearch, Inc. Rapid, quantitative peptide synthesis using mixed anhydrides
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4619828A (en) 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
EP0109350B1 (fr) 1982-11-10 1991-10-16 Mitsubishi Jukogyo Kabushiki Kaisha Alliage nickel-chrome
US4762713A (en) * 1983-07-05 1988-08-09 The University Of Rochester Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
EP0200249B1 (fr) 1985-04-17 1988-10-19 Akzo N.V. Procédé d'application d'une composition de marquage routier
DE3518706A1 (de) 1985-05-24 1986-11-27 Kernforschungszentrum Karlsruhe Gmbh, 7500 Karlsruhe Verfahren zur herstellung von formkoerpern mit verbesserten, isotropen eigenschaften
US4814276A (en) * 1986-04-25 1989-03-21 Becton, Dickinson And Company Selective medium for growth of neisseria
AU640118B2 (en) 1988-12-19 1993-08-19 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur Meningococcal class 1 outer-membrane protein vaccine
US4963534A (en) * 1989-05-19 1990-10-16 Merck & Co., Inc. Process for solubilizing polyanoinic bacterial polysaccharides in aprotic solvents
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
JP2631035B2 (ja) 1991-03-12 1997-07-16 アメリカ合衆国 多糖類−タンパク質複合体
SK18594A3 (en) 1991-08-16 1994-08-10 Merck & Co Inc Method of production of capsular polysacharide without lipid and endotoxine
US5314811A (en) * 1992-07-13 1994-05-24 Merck & Co., Inc. Process for converting lipid-containing bacterial capsular polysaccharide into lipid-free polysaccharide
US5422427A (en) * 1991-09-17 1995-06-06 The United States Of America As Represented By The United States Department Of Health And Human Services Pneumococcal fimbrial protein A
FR2682388B1 (fr) 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
SK280702B6 (sk) * 1992-05-23 2000-06-12 Smithkline Beecham Biologicals S. A. Kombinovaný očkovací prostriedok obsahujúci povrch
US5445817A (en) 1992-08-21 1995-08-29 The United States Of America As Represented By The Department Of Health And Human Services Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines
DK0658118T3 (da) * 1992-08-31 2002-05-06 Baxter Healthcare Sa Vaccine mod Neisseria meningitidis, gruppe C
TR199701547T1 (xx) 1995-06-07 1998-03-21 Smithkline Beecham Biologicals S.A. Polisakarit antijen protein e�leni�i i�eren a��.
US5811102A (en) * 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
US20020054884A1 (en) * 1995-06-23 2002-05-09 Smithkline Beecham Biologicals, Sa Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
PT833662E (pt) 1995-06-23 2001-09-28 Smithkline Beecham Biolog Uma composicao vacinal compreendendo um antigenio polissacaridico conjugado adsorvido a fosfato de aluminio
US6248334B1 (en) * 1997-01-08 2001-06-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
KR100593466B1 (ko) 1997-01-21 2007-04-25 파스퇴르 메리오 세룸 에 박신 다당류-펩타이드접합체
CA2278626C (fr) 1997-01-24 2010-04-27 Schweiz. Serum- & Impfinstitut Bern Nouvelle methode pour isoler des polysaccharides
US6403306B1 (en) * 1997-04-09 2002-06-11 Emory University Serogroup-specific nucleotide sequences in the molecular typing of bacterial isolates and the preparation of vaccines thereto
WO1998047530A2 (fr) 1997-04-24 1998-10-29 Henry M. Jackson Foundation For The Advancement Of Military Medicine Couplage de proteines non modifiees a des polysaccharides derives d'haloacyle ou de dihaloacyle pour la preparation de vaccins renfermant des proteines-polysaccharides
JP4173560B2 (ja) 1997-05-28 2008-10-29 カイロン ソチエタ ア レスポンサビリタ リミタータ アミノ酸源として酵母または大豆抽出物を含み、動物起源のタンパク質複合体を含まない培養培地
WO1998058670A1 (fr) * 1997-06-24 1998-12-30 Chiron Corporation Procedes permettant d'immuniser des adultes grace a des compositions de vaccins anti-meningococcique
US5965714A (en) 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
DK1051506T4 (da) 1997-12-23 2019-10-21 Pfizer Ireland Pharmaceuticals Fremgangsmåder til ekstraktion og isolering af bakterielle kapselpolysaccharider til anvendelse som vacciner eller bundet til proteiner som konjugatvacciner
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US6146902A (en) * 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
ES2347428T3 (es) 1999-02-01 2010-10-29 EISAI R&D MANAGEMENT CO., LTD. Compuestos coadyuvantes inmunologicos.
AR022963A1 (es) 1999-03-19 2002-09-04 Smithkline Beecham Biolog Vacuna
DK2270172T3 (en) 1999-05-19 2016-02-29 Glaxosmithkline Biolog Sa Combination Compositions of Neisseria.
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9925559D0 (en) 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
DE60039450D1 (de) 1999-12-02 2008-08-21 Novartis Vaccines & Diagnostic Zusammensetzungen und methoden zur stabilisierung von biologischen molekülen nach lyophilisierung
US6800455B2 (en) * 2000-03-31 2004-10-05 Scios Inc. Secreted factors
HU227893B1 (en) 2000-06-29 2012-05-29 Glaxosmithkline Biolog Sa Vaccine compositions
DK2332581T3 (en) * 2001-01-23 2015-10-05 Sanofi Pasteur Inc Tri- or tetravalent meningococcal polysaccharide-crm197 conjugate vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination

Also Published As

Publication number Publication date
BE2015C077I2 (fr) 2021-02-04
US9844601B2 (en) 2017-12-19
FR12C0072I2 (fr) 2013-11-01
IS6881A (is) 2003-07-22
CY2012030I2 (el) 2016-08-31
HUP0302999A2 (hu) 2003-12-29
IL225522A (en) 2016-04-21
LU92108I9 (fr) 2019-01-15
FR15C0094I2 (fr) 2017-05-19
EP2957300A3 (fr) 2016-03-30
SI21352A (sl) 2004-06-30
US8734813B2 (en) 2014-05-27
NO20033816L (no) 2003-09-11
EP2957300B1 (fr) 2021-07-14
US8741314B2 (en) 2014-06-03
LT5177B (lt) 2004-11-25
BE2022C502I2 (fr) 2023-04-12
IL157060A0 (en) 2004-02-08
HRP20030598A2 (en) 2005-06-30
WO2002058737A3 (fr) 2003-05-22
UA92579C2 (ru) 2010-11-25
HUS1600040I1 (hu) 2019-05-28
JP5795721B2 (ja) 2015-10-14
ES2892316T3 (es) 2022-02-03
PL226184B1 (pl) 2017-06-30
LT2003071A (en) 2004-08-25
CR7035A (es) 2008-11-25
US10143757B2 (en) 2018-12-04
HU230490B1 (hu) 2016-08-29
IL225522A0 (en) 2013-06-27
PT2332581E (pt) 2015-10-16
US20030068336A1 (en) 2003-04-10
DK1355673T3 (da) 2012-09-17
IL157060A (en) 2013-04-30
PT1355673E (pt) 2012-08-31
JP2011140522A (ja) 2011-07-21
US20130216571A1 (en) 2013-08-22
AU2007216743A1 (en) 2007-10-04
BRPI0206672B1 (pt) 2018-11-06
JP2014043475A (ja) 2014-03-13
HUP0302999A3 (en) 2011-05-30
CN100556459C (zh) 2009-11-04
NO20033816D0 (no) 2003-08-27
JP2014065745A (ja) 2014-04-17
YU66103A (sh) 2006-05-25
FR22C1001I1 (fr) 2022-02-18
CA2435681A1 (fr) 2002-08-01
WO2002058737A2 (fr) 2002-08-01
EP2332581A1 (fr) 2011-06-15
ES2544979T3 (es) 2015-09-07
KR100947751B1 (ko) 2010-03-18
BRPI0206672B8 (pt) 2021-05-25
MX341760B (es) 2016-09-02
DK2332581T3 (en) 2015-10-05
US8999354B2 (en) 2015-04-07
US10617766B2 (en) 2020-04-14
GEP20053691B (en) 2005-12-12
EP1355673B1 (fr) 2012-05-30
KR20030084913A (ko) 2003-11-01
BE2012C050I2 (fr) 2021-03-23
EP2957300A2 (fr) 2015-12-23
JP2016128526A (ja) 2016-07-14
NZ622900A (en) 2015-11-27
PL373710A1 (en) 2005-09-05
EA200300827A1 (ru) 2004-06-24
US20150174259A1 (en) 2015-06-25
AP1897A (en) 2008-10-10
EP1355673A2 (fr) 2003-10-29
US20130224241A1 (en) 2013-08-29
BR0206672A (pt) 2005-05-10
CN1610560A (zh) 2005-04-27
CY1113072T1 (el) 2015-08-05
LV13128B (en) 2004-07-20
US20190060475A1 (en) 2019-02-28
EA006947B1 (ru) 2006-06-30
US20130177588A1 (en) 2013-07-11
US20180154010A1 (en) 2018-06-07
RO122761B1 (ro) 2010-01-29
LU92108I2 (fr) 2013-01-29
ZA200306176B (en) 2005-03-30
US8722062B2 (en) 2014-05-13
HRP20030598B1 (hr) 2013-05-31
NZ602682A (en) 2014-05-30
US20140308311A1 (en) 2014-10-16
FR12C0072I1 (fr) 2013-01-04
EP2332581B1 (fr) 2015-07-01
OA12590A (en) 2006-06-08
KR20090029857A (ko) 2009-03-23
CY2012030I1 (el) 2015-08-05
ES2388848T3 (es) 2012-10-19
CA2435681C (fr) 2011-06-21
US20160000928A1 (en) 2016-01-07
KR100947757B1 (ko) 2010-03-18
JP2014043474A (ja) 2014-03-13
MXPA03006561A (es) 2004-10-15
AP2003002829A0 (en) 2003-09-30
TNSN03041A1 (en) 2005-12-23
JP2005504718A (ja) 2005-02-17
US9173955B2 (en) 2015-11-03
ECSP034701A (es) 2003-10-28
AU2010219288A1 (en) 2010-09-23

Similar Documents

Publication Publication Date Title
BE2017C057I2 (fr)
BE2017C051I2 (fr)
BE2017C032I2 (fr)
BE2016C051I2 (fr)
FR15C0094I1 (fr)
BE2015C046I2 (fr)
BE2014C036I2 (fr)
BE2014C026I2 (fr)
BE2014C004I2 (fr)
BE2014C006I2 (fr)
BE2012C022I2 (fr)
BE2011C034I2 (fr)
JP2002191463A5 (fr)
BE2007C047I2 (fr)
AU2002307149A8 (fr)
JP2001356840A5 (fr)
JP2001350577A5 (fr)
JP2001337812A5 (fr)
BE2014C008I2 (fr)
BE2016C043I2 (fr)
CH1379220H1 (fr)
BE2016C021I2 (fr)
JP2001286713A5 (fr)
BE2012C051I2 (fr)
JP2002151524A5 (fr)